Checkpoint inhibition and melanoma: Considerations in treating the older adult. Review uri icon

Overview

abstract

  • The incidence of melanoma and associated mortality rate from advanced disease in older adults is increasing over time. Checkpoint inhibitors have demonstrated a survival benefit for the treatment of stage IV or unresectable stage III disease and have become one of the standards of care. Data suggests that adults aged 65 and older benefit from treatment with checkpoint inhibitors without an increased incidence in adverse events. However, clinicians should be aware of the potential side effects of this class of medications and how to manage them in older adults.

publication date

  • May 11, 2017

Research

keywords

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Melanoma

Identity

PubMed Central ID

  • PMC5629004

Scopus Document Identifier

  • 85021797284

Digital Object Identifier (DOI)

  • 10.1016/j.jgo.2017.04.003

PubMed ID

  • 28506536

Additional Document Info

volume

  • 8

issue

  • 4